Adebelimab plus chemo for extensive-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new immunotherapy drug (Adebelimab) combined with standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if this combination works better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small cell lung cancer (confirmed by biopsy or cytology).
- You are between 18 and 75 years old.
- You have not had any previous chemotherapy or other systemic treatment for extensive-stage small cell lung cancer.
- You can take care of yourself (ECOG performance status 0 or 1).
- You have at least one tumor that can be measured on a scan.
- Your major organs (like bone marrow, liver, kidneys) are working well enough, as shown by recent blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of immunotherapy (adebrelimab), a targeted drug (famitinib), and standard chemotherapy for people with extensive stage small cell lung cancer who have not had treatment before. The goal is to see if this combination works better than chemotherapy alone.
This trial is testing a new approach for extensive-stage small cell lung cancer (SCLC) that has not been treated before. It combines a high-dose chemotherapy regimen with a drug called adebrelimab (an immunotherapy) and a stem cell transplant to help your body recover. The goal is to see if this powerful combination can work better than standard treatment.
This trial tests a combination of three drugs (adebrelimab, irinotecan liposome, and famitinib) for people with extensive-stage small cell lung cancer whose disease got worse after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests a new drug called Adebelizumab (an immunotherapy) combined with chemotherapy and radiation for people with extensive stage small cell lung cancer. The goal is to see if this combination helps shrink tumors and improves survival.
This trial tests a combination of two drugs (adebrelimab and etoposide capsules) as maintenance therapy for people with extensive-stage small cell lung cancer who have not progressed after initial treatment. It may help extend the time before the cancer grows back.
This trial tests a combination of three drugs (apatinib, adebrelimab, and EC chemotherapy) as the first treatment for extensive-stage small cell lung cancer that has spread. The goal is to see if this combination works better than standard treatments alone.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.